Form 4: Xilio Therapeutics Director Paul J. Clancy Reports Stock Option Grant

Paul J. Clancy, a director of Xilio Therapeutics, reported the acquisition of a stock option for 25,000 shares on June 14, 2024.

Summary

• On June 17, 2024, a Form 4 filing was submitted to the SEC by Paul J. Clancy, a director of Xilio Therapeutics, Inc.
• The filing reports a transaction that occurred on June 14, 2024, where Clancy acquired a stock option to purchase 25,000 shares of Xilio Therapeutics common stock at an exercise price of $1.02 per share.
• The option vests on the earlier of June 14, 2025, or the date of the Issuer's next annual meeting of stockholders following the grant date, contingent upon Clancy's continued service to the Issuer.
• Clancy also granted a Limited Power of Attorney to Ren Russo, Christopher Frankenfield, Kevin Brennan, and Julia Walcott to handle Section 16 reporting obligations.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to directors can align their interests with those of shareholders, incentivizing them to work towards increasing the company's value.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management and board member interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and officers in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of the option, contingent on continued service and tied to the annual meeting, is a typical arrangement to ensure ongoing commitment.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to act in ways that benefit shareholders.

Key Dates